Improved OS With Dacomitinib vs Gefitinib in Selected EGFR+ NSCLC

Researchers in Hong Kong found dacomitinib was associated with longer OS than gefitinib in patients with advanced EGFR+ NSCLC.

Source: CancerNetwork - June 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news